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Abstract
Objectives. There is a lack of published data regarding patient interaction in basic scientific research,
including methodologies for simple, cost-effective interactions and the outcomes of such studies.
Therefore, we aimed to evaluate the ease of generating patient opinion data on specific scientific
research projects whilst establishing a template for other groups to follow. Our secondary objective
was to assess which research topics are of most interest to patients with SLE and/or APS.
Methods. Through patient-based interactions, we developed a lay summary of a mechanistic research
proposal and a set of associated questions to assess patient opinion on this research topic. We disse-
minated the questions as an online survey with associated lay summary through patient-based charity
websites and social media. The survey was open for 3 weeks.
Results. Of 527 respondents, 520 reported having SLE or APS. The patient response to the research proposal
was overwhelmingly positive, with the majority expressing strong interest in the mechanistic aspect of the
project. Analysis of free text box responses confirmed that the most popular research topics for patients were
as follows: treatment, genetics, triggers, diagnosis and mechanistic research. Interestingly, patient interest in
disease mechanisms featured more frequently than clinical topics, such as management of disease flares.
Conclusion. It is possible to conduct short-term, valuable patient engagement at low cost, using an online
survey and social media. This methodology may form a good template for future patient engagement. The
volume and distribution of positive response shows that patients are interested in mechanistic research.
Key words: systematic lupus erythematosus and autoimmunity, antiphospholipid syndrome, patient attitude
to health, study design, Social media.
Introduction
Patient and public involvement (PPI) is considered a cor-
nerstone of clinical research [1], enabling researchers to
identify and address questions most relevant to patients
[2, 3]. In contrast, PPI in mechanistic research is
less common, primarily owing to perceived challenges
among researchers [4]. In particular, PPI is often consid-
ered expensive and time consuming, and in diseases
with a relatively low incidence, such as SLE, reaching a
large audience can be challenging. In addition to these
methodological barriers, there is a need for researchers
to refine the science of patient input to produce quanti-
tative data [5]. To overcome these problems, a template
Key messages
. Social media is a powerful, cheap and effective tool for patient and public engagement.
. Patients with SLE/APS are interested in mechanistic approaches to research.
. Large amounts of relevant feedback can be collected rapidly from patients with rheumatic diseases.
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for quick, effective collection of measurable patient
opinions is required. We set out to prove that the proc-
ess can be inexpensive, expansive and inclusive.
Social media has become an established means of
online communication over recent years. Platforms such
as Twitter and Facebook allow users to publish their
own content directly to a worldwide forum. The use of
social media in the medical profession is also increas-
ing. In 2014, a study reported that 72% of Canadian
oncology physicians used social media regularly [6].
Furthermore, patients now frequently use social media
to gain information and interact with online health com-
munities and support groups, such as the APS Support
UK community and various charity Twitter groups [7,8].
Therefore, we developed and undertook a PPI project
with measurable outcomes using social media to gauge
the relevance of our proposed mechanistic, non-clinical,
basic science research into the effect of autoantibodies
upon the interaction of complement and coagulant ser-
ine proteases in APS and SLE and, in doing so, to




We designed a lay summary describing our mechanistic
research proposal relevant to patients with SLE and/or
APS and a nine-item questionnaire in the form of a sur-
vey to gauge the interest of patients in a range of
related and more general research topics. The aim was
to reach the maximal number of patients in the shortest
possible time for minimal cost. We used social media
and liaised with relevant patient-based charities (LUPUS
UK and APS Support UK) to increase dissemination.
Ethical review was not required because no patient-
identifiable data were collected. We also accessed the
UK Health Research Authority decision tool (available
online at https://www.hra.nhs.uk/approvals-amendments
/what-approvals-do-i-need/), which confirmed that ethi-
cal approval was not necessary for this study.
Question design and lay summary
The proposed questionnaire and lay summary were
refined through consultation with an expert patient,
patient charity representatives. The survey was limited
to nine questions to reduce the likelihood of participants
abandoning it before completion. The first question
aimed to identify patient disease groups, followed by
questions about the importance of activity markers, of
antibody testing for the patient and for the clinician and
future therapeutic advances. To ensure quantitative data
collection, questions were formatted to capture answers
as either a rating of the importance of research ques-
tions on a numerical scale of 1–10 (with 10 being of
highest importance) or to answer yes or no (Table 1).
Qualitative data were also collected through a free
text box, allowing participants to provide further detail
of their opinions regarding research questions not
answered elsewhere.
Response capture
The survey was hosted online (via the Survey Monkey
website, www.surveymonkey.com) and circulated through
commonly used social media platforms, namely Twitter
(www.twitter.com) and Facebook (www.facebook.com). In
addition, the lay summary was hosted with links to the
survey on the charity websites of LUPUS UK (www.lupu
suk.org.uk) and APS Support UK (www.aps-support.org.
uk). The survey remained open for a 4-week period from
5 March 2017 to the 5 April 2017 (inclusive), during
which patient responses were captured. To ensure the
validity of data, individual Internet Protocol addresses
were allowed a single submission, thus preventing multi-
ple attempts by the same participant. A preliminary ques-
tion asking the respondent to confirm a diagnosis of SLE
and/or APS was included to reduce the risk of capturing
data from other patient groups, healthy individuals or
relatives.
Analysis of response
Quantitative data were analysed using Microsoft Excel
2016 software. Qualitative data were reviewed and
assigned to predetermined research categories by
TABLE 1 The full questions and options of the question-
naire hosted online for patients
Question Answers
How long have you had lupus
and/or APS?
<5 years, 5–10 years,
>10 years
How valuable do you think
research to identify new blood
tests to measure disease
activity for lupus and APS is?
1–10
How valuable do you think it is
to know if you are positive for
autoantibodies that may influ-
ence your treatment?
1–10
How important do you think it is
to know the effects your auto-
antibodies may have on your
treatment?
1–10
Do you think it is important for




Would you take an anti-FXa
drug if you thought it would
help treat your lupus or APS?
Yes/no/if recommended
by a clinician




What research questions do
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T.C.R.M. and checked for scientific/clinical accuracy by
C.W. and I.G. Any disagreements were resolved by dis-
cussion, and where comments were felt to relate to
more than one research category, the comment was
placed in the appropriate number of relevant categories.
Denominators relate to the total number of responses
per question.
Results
Total expenditure was £26, which covered the costs of
accessing and downloading data collected from the
online survey.
Data capture
A total of 527 responses were captured across a
4-week period. Peaks of 104 and 152 responses per
day on days 1 and 9 of the survey were correlated with
the days on which the questionnaire was posted on dif-
ferent charity Twitter feeds. The original tweet on Twitter
gathered 127 total engagements and was seen 2072
times on that platform.
Disease duration
Of the 527 responses, almost all (520, 98.7%) respond-
ents confirmed having SLE and/or APS. The majority of
patients had a disease duration of >10 years (255/520;
48%). Disease duration of 5–10 years was reported in
116/520 (22%), and those with a diagnosis of <5 years
accounted for 149/520 (28%) of responses (Fig. 1A).
The remaining 1.3% (7/527) of responders reported hav-
ing neither condition, so their responses were excluded.
Opinions on mechanistic research
and autoantibodies
The lay summary described a project based on the
study of antibodies to serine proteases, their potential
role in SLE and APS pathogenesis and possible use as
biomarkers of disease activity. When asked how valua-
ble they considered this research into new blood tests
for disease activity in lupus or APS, the average
response was 9.5/10, with 87% (453/519) of responders
scoring 9 or higher. Only four respondents gave a value
below 5/10. Similar responses were seen for questions
regarding how important they considered knowledge of
their antibody status (9.5/10, 454/519, 87%) or the
importance of clinicians knowing the effects that
antibodies may have on informing treatment decisions
(9.5/10, 456/518, 88%). Only two patients scored all
three questions as <7/10.
Considerations of new therapies
Regarding new treatments, we posed a question asking
whether patients would take a serine protease blocking
drug for treatment of SLE or APS. Only 1.4% replied
negatively (7/517), with the remaining 98.6% (510/517)
split between yes (41%, 212/517) and if recommended
by a clinician (57.8%, 298/517). Eighty-eight per cent
(454/514) of patients responded positively when asked
whether research regarding antibody positivity and
mechanisms of action was felt to be relevant to their
disease (Fig. 1B).
Other opinions
From 277 individual free-text responses, 464 comments
were extracted. Ten were excluded for being questions
about personal circumstances. The remaining comments
were grouped into 22 categories according to content.
These included treatment (18.9%, 86/464), genetics
(12.3%, 56/464), triggers (11.0%, 50/464), diagnosis
(8.3%, 38/464), mechanisms (6.1%, 28/464) and man-
agement (5.7%, 26/464). The full list of categories is
summarized in Fig. 1B.
Discussion
Overall, we found this PPI activity to be a simple, inex-
pensive and time-efficient process, confirming that
patients are interested in mechanistic research. To date
there is a surprising lack of published data regarding
PPI in basic science projects regarding mechanistic
studies. Often it is assumed that patients will find this
sort of study less interesting or relevant when compared
with clinical research; consequently, PPI may be
overlooked.
The potential time and financial constraints involved in
generating PPI are also commonly reported barriers.
Various studies have attempted to address this imbal-
ance [4] through several approaches, with varying
degrees of success [9]; for example, Elwyn et al. [10]
attempted to assess patient interest in research ques-
tions in asthma. They conducted a survey by mailing it
to 1146 participants and posting it online on a relevant
charity website for 3 weeks. The entire postal study was
open for a total of 3 months. Of 370 responses, 211
were from the online website link and 103 responses
were discarded because they were deemed to contain
irrelevant information [10]. This study cost a total of
£29 000 to conduct and demonstrates the potentially
complex and costly nature of patient engagement. In
contrast, we obtained 527 responses, discarded only
seven and spent a total of £26 over a 3-week data col-
lection period.
Through the use of social media, we have demon-
strated that it is possible to canvas the opinions of a
large group of patients in a short period of time at very
little expense. The high volume of responses is even
more remarkable considering the low prevalence of SLE.
Conducting this survey on a face-to-face basis would
have required considerably more time and cost.
In addition, our results have identified areas of interest
to patients in SLE/APS that we assumed to be less rele-
vant or important to patients because they do not
directly translate into a new therapy. It was clear from
free-text comments that patients are interested in mech-
anistic approaches to research as well as diagnostic
and therapeutic approaches. This finding has not
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previously been reported. Patients also expressed an
interest in genetic research, specifically regarding trans-
mission of their diseases to their progeny. It should be
noted here, however, that it is possible patient opinion
has been influenced by the associated explanation and,
as such, more in-depth research is required to confirm
these trends.
To overcome problems that can occur owing to analy-
sis of qualitative data, that is, misinterpretation and mis-
understandings seen in the study by Elwyn et al. [10],
patient contact and lack of patient understanding of the
underlying research question, we provided a lay sum-
mary of the research that had been developed in
collaboration with patient experts and relevant charities.
In addition, we ensured that the results gained were pre-
dominantly binary or numerical, allowing for data analy-
sis in a number of ways and ensuring a measurable
outcome.
In contrast, data collected in the free text box
were qualitative. To safeguard these data from mis-
interpretation, responses were analysed by one member
of the team in order to assign the comments to
FIG. 1 Research outcomes of patient engagement
Various disease- and research-related outcomes are shown. (A) Responses from patients when presented with a
research project regarding antibody positivity and potential mechanisms. (B) Research topics raised by patients and
their frequency in the survey (the length of the bar).
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categories before two clinicians independently checked
and confirmed the correct scientific/clinical
categorization. As with the study of Elwyn et al. [10], we
found that some patients included comments relating to
their personal circumstances, although at a much lower
proportion in our study. This finding may be attributable
to the more defined research project detail we supplied
in the lay summary along with the questionnaire.
The responses we received were overwhelmingly pos-
itive, with 12 patients using the text box to comment on
how beneficial it was to see such research being under-
taken. Patients seemed enthusiastic to be involved,
even re-posting the survey to message boards for other
patients to access. The survey was also shared world-
wide by patient associations, resulting in a global
response.
This approach does, however, have limitations; for
example, it relies on familiarity with information technology,
the Internet and social media platforms. Furthermore, basic
English language and literacy levels are required (although
there is potential for future surveys to be translated). There
is also the risk of targeting only the specific demographic
of the population who regularly use social media. This risk
might bias towards a younger population, who tend to use
these platforms more than older patients. For instance, the
office of government statistics states that in 2017 96% of
people aged 16–24 years used social media platforms
compared with only 68% aged 45–54 years (www.ons.
gov.uk). In an attempt to account for this potential bias,
we included a question regarding disease duration.
Interestingly, the majority of responses were from patients
with a disease duration of >10 years. Given that the mean
age at which patients develop SLE or APS is 30 years,
the majority of our respondents with disease duration of
>10 years are likely to be in their fifth decade. Therefore,
we do not think that we have encountered a younger age
bias; however, without collecting age-of-onset data this is
hard to prove conclusively.
Tunnicliffe et al. [11] recently published a study looking
at the research priorities of young patients with SLE.
Using face-to-face semi-structured interviews with 26 par-
ticipants they identified seven themes and prioritization of
research on alleviating poor psychological outcomes. Our
research methods were very different from theirs in terms
of the number of participants, broader age range and
contact online rather than face to face. It is important to
recognize that a mixture of different research methods, as
exemplified by these two contrasting studies, should be
used to investigate the important area of patient preferen-
ces and opinions regarding research in SLE.
We guarded against confounding by non-SLE/APS
patients answering the survey by asking participants to
self-confirm their diagnosis, and seven respondents
answered that they had neither SLE nor APS.
We designed the survey to make this question manda-
tory before completing the remaining questions. The one
bias we could not guard against entirely was response
bias [7]; however, research suggests that criticism may
be raised against most questionnaire-based studies.
Equally, it could be suggested that the context of the
survey might have influenced question answers given
the associated text; however, this would be true of any
PPI undertaken in the context of a disease.
In conclusion, this PPI exercise demonstrates that a
mechanistic research project is valuable and highly rele-
vant to patients with SLE/APS. Furthermore, we demon-
strate that a social media-based survey approach is a
powerful tool, which enables the opinion of a large num-
ber of patients to be captured in a short time frame with
minimal cost. This approach could be adopted by other
groups, ensuring that patients are given an active role in
directing future research.
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